Skip to main content Skip to main navigation menu Skip to site footer

Laporan kasus: komplikasi euglycemic diabetic ketoacidosis pada pasien diabetes melitus tipe 2 dengan riwayat penggunaan SGLT-2 inhibitor

  • Komang Siska Lestari Sugitha ,
  • I Made Pande Dwipayana ,
  • Wira Gotera ,
  • Made Ratna Saraswati ,
  • I Made Siswadi Semadi ,
  • Ida Bagus Aditya Nugraha ,
  • Ketut Suastika ,
  • Anak Agung Gede Budhiarta ,

Abstract

Introduction: Euglycemic Diabetic Ketoacidosis (EuDKA) is an emergency condition in diabetes mellitus. Normal blood glucose often complicates and delays diagnosis. Use of SGLT-2 inhibitors is one of the identified risk factors.

Case presentation: This case report describes a diabetic patient with an episode of EuDKA secondary to empaglifozin use. The patient was treated with intravenous hydration using normal saline and parallel intravenous insulin infusion with 5% dextrose. EuDKA should be considered in patients with unexplained metabolic acidosis and SGLT-2 inhibitors should be discontinued when a diagnosis of EuDKA is established.

Conclusion: The patient's condition continued to improve until he was allowed to be discharged with basal bolus insulin taken home.

 

Pendahuluan: Euglycemic Diabetic Ketoacidosis (EuDKA) adalah kondisi darurat pada diabetes mellitus. Glukosa darah normal sering mempersulit dan menunda diagnosis. Penggunaan SGLT-2 inhibitor adalah salah satu faktor risiko yang diidentifikasi.

Presentasi kasus: Laporan kasus ini menggambarkan pasien diabetes dengan episode EuDKA sekunder akibat penggunaan empaglifozin. Pasien diobati dengan hidrasi intravena menggunakan saline normal dan infus insulin intravena paralel dengan dekstrosa 5%. EuDKA harus dipertimbangkan pada pasien dengan asidosis metabolik yang tidak dapat dijelaskan dan SGLT-2 inhibitor harus dihentikan ketika diagnosis EuDKA ditegakkan.

Simpulan: Kondisi pasien terus membaik sampai diizinkan untuk dipulangkan dengan membawa pulang insulin bolus basal.

References

  1. Dwipayana IMP, Semadi IMS. Profil Penderita Diabetes Melitus Tipe 2 dengan Hipoglikemia di Rumah Sakit Rujukan Tersier di Bali Indonesia. MEDICINA. 2024;55(1):35–9.
  2. Setiyawan IMK. Hemodialisis pada ketoasidosis diabetik dengan Acute Kidney Injury Stage Failure : Case Series dari Bali , Indonesia. MEDICINA. 2024;55(1):5–10.
  3. Rawla P, Vellipuram AR, Bandaru SS, Pradeep Raj J. Euglycemic diabetic ketoacidosis: a diagnostic and therapeutic dilemma. Endocrinol diabetes Metab case reports. 2017;2017:17–81. Available from: https://pubmed.ncbi.nlm.nih.gov/28924481
  4. Wojtas C, Rasarmos AP, Naddaf N. Sodium-Glucose Transport Protein 2 Inhibitors Association with Euglycemic Diabetic Ketoacidosis. Case Rep Endocrinol. 2023;2023:6835882. Available from: https://pubmed.ncbi.nlm.nih.gov/36890810
  5. Yu X, Zhang S, Zhang L. Newer Perspectives of Mechanisms for Euglycemic Diabetic Ketoacidosis. Int J Endocrinol. 2018;2018:7074868.
  6. Blau JE, Tella SH, Taylor SI, Rother KI. Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data. Diabetes Metab Res Rev. 2017/09/29. 2017;33(8):10.1002/dmrr.2924. Available from: https://pubmed.ncbi.nlm.nih.gov/28736981
  7. Burke KR, Schumacher CA, Harpe SE. SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature. Pharmacotherapy. 2017;37(2):187–94.
  8. Somagutta MR, Agadi K, Hange N, Jain MS, Batti E, Emuze BO, et al. Euglycemic Diabetic Ketoacidosis and Sodium-Glucose Cotransporter-2 Inhibitors: A Focused Review of Pathophysiology, Risk Factors, and Triggers. Cureus. 2021;13(3):e13665–e13665. Available from: https://pubmed.ncbi.nlm.nih.gov/33824816
  9. Diaz-Ramos A, Eilbert W, Marquez D. Euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitor use: a case report and review of the literature. Int J Emerg Med. 2019;12(1):27. Available from: https://pubmed.ncbi.nlm.nih.gov/31488052
  10. Nasa P, Chaudhary S, Shrivastava PK, Singh A. Euglycemic diabetic ketoacidosis: A missed diagnosis. World J Diabetes. 2021;12(5):514–23. Available from: https://pubmed.ncbi.nlm.nih.gov/33995841
  11. Jaber JF, Standley M, Reddy R. Euglycemic Diabetic Ketoacidosis in Pregnancy: A Case Report and Review of Current Literature. Vol. 2019, Case reports in critical care. United States; 2019. p. 8769714.
  12. Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition. Diabetes Care. 2015/06/15. 2015;38(9):1687–93. Available from: https://pubmed.ncbi.nlm.nih.gov/26078479
  13. Alkatheeri A, Alseddeeqi E. Euglycemic diabetic ketoacidosis induced by sodium-glucose cotransporter 2 inhibitor in the setting of prolonged fasting: a case report. J Med Case Rep. 2022;16(1):138. Available from: https://pubmed.ncbi.nlm.nih.gov/35346357
  14. Sanchez DSM, Larios JFDP, Salas JMG, Salazar JAD, García GL. Euglycemic Diabetic Ketoacidosis in Patients Taking Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors: Review of the Literature. Int J Med Sci Clin Res Stud. 2023;3(4):697–700.
  15. Altowayan WM. Empagliflozin induced euglycemic diabetic ketoacidosis. A case reports. Ann Med Surg. 2022;84:104879. Available from: https://pubmed.ncbi.nlm.nih.gov/36582864
  16. Scheen AJ. Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin Pharmacokinet. 2014;53(3):213–25. Available from: https://pubmed.ncbi.nlm.nih.gov/24430725
  17. Wang KM, Isom RT. SGLT2 Inhibitor-Induced Euglycemic Diabetic Ketoacidosis: A Case Report. Kidney Med. 2020;2(2):218–21. Available from: https://pubmed.ncbi.nlm.nih.gov/32734242
  18. Fukuda M, Nabeta M, Muta T, Fukami K, Takasu O. Euglycemic diabetic ketoacidosis caused by canagliflozin: a case report. Int J Emerg Med. 2020;13(1):2. Available from: https://pubmed.ncbi.nlm.nih.gov/31969112
  19. Alhemeiri M, Alseddeeqi E. Euglycemic Diabetic Ketoacidosis after Discontinuing SGLT2 Inhibitor. Case Rep Endocrinol. 2022;2022:4101975. Available from: https://pubmed.ncbi.nlm.nih.gov/35282610
  20. Simes BC, MacGregor GG. Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide. Diabetes Metab Syndr Obes. 2019;12:2125–36. Available from: https://pubmed.ncbi.nlm.nih.gov/31686884
  21. Selwyn J, Pichardo-Lowden AR. Managing Hospitalized Patients Taking SGLT2 Inhibitors: Reducing the Risk of Euglycemic Diabetic Ketoacidosis. Diabetology. 2023;4(1):86–92. Available from: http://dx.doi.org/10.3390/diabetology4010010
  22. Latif A, Gastelum AA, Sood A, Reddy JT. Euglycaemic diabetic ketoacidosis in a 43-year-old woman with type 2 diabetes mellitus on SGLT-2 inhibitor (empagliflozin). BMJ Case Rep. 2020;13(6):e235117. Available from: https://pubmed.ncbi.nlm.nih.gov/32513767
  23. Venkatachalam B, Venkatesh N. Euglycemic Diabetic Ketoacidosis (EDKA): An easy to miss complication in Diabetic patients on Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors. J Med Sci. 2022;1(02):17–22.

How to Cite

Sugitha, K. S. L. ., Dwipayana, I. M. P., Gotera, W. ., Saraswati, M. R. ., Semadi, I. M. S. ., Nugraha, I. B. A., Suastika, K., & Budhiarta, A. A. G. . (2024). Laporan kasus: komplikasi euglycemic diabetic ketoacidosis pada pasien diabetes melitus tipe 2 dengan riwayat penggunaan SGLT-2 inhibitor. Medicina, 55(1), 47–53. https://doi.org/10.15562/medicina.v55i1.1296

HTML
510

Total
282

Share

Search Panel

Komang Siska Lestari Sugitha
Google Scholar
Pubmed
Medicina Journal


I Made Pande Dwipayana
Google Scholar
Pubmed
Medicina Journal


Wira Gotera
Google Scholar
Pubmed
Medicina Journal


Made Ratna Saraswati
Google Scholar
Pubmed
Medicina Journal


I Made Siswadi Semadi
Google Scholar
Pubmed
Medicina Journal


Ida Bagus Aditya Nugraha
Google Scholar
Pubmed
Medicina Journal


Ketut Suastika
Google Scholar
Pubmed
Medicina Journal


Anak Agung Gede Budhiarta
Google Scholar
Pubmed
Medicina Journal